LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Rated “Moderate Buy” by Wall Street Analysts

LENZ Therapeutics, Inc. (NASDAQ:LENZ) has received an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $28.80.

A number of equities research analysts recently commented on LENZ shares. Zacks Research upgraded shares of LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Piper Sandler cut their price target on shares of LENZ Therapeutics from $12.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, August 12th. HC Wainwright restated a “buy” rating on shares of LENZ Therapeutics in a research report on Tuesday, July 7th. Citigroup reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research note on Wednesday, August 12th. Finally, Weiss Ratings cut LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 9th.

Institutional Investors Weigh In On LENZ Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC increased its stake in shares of LENZ Therapeutics by 16.0% during the second quarter. Squarepoint Ops LLC now owns 1,747,096 shares of the company’s stock valued at $9,924,000 after buying an additional 240,597 shares during the period. Corient Private Wealth LP lifted its stake in LENZ Therapeutics by 101.1% in the second quarter. Corient Private Wealth LP now owns 74,931 shares of the company’s stock worth $426,000 after acquiring an additional 37,672 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in LENZ Therapeutics in the second quarter valued at $102,000. Hsbc Holdings PLC boosted its holdings in LENZ Therapeutics by 264.5% in the second quarter. Hsbc Holdings PLC now owns 79,811 shares of the company’s stock valued at $449,000 after acquiring an additional 57,917 shares in the last quarter. Finally, Jefferies Financial Group Inc. purchased a new position in LENZ Therapeutics during the 2nd quarter valued at $1,138,000. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Trading Down 1.1%

NASDAQ LENZ opened at $3.72 on Friday. The firm has a market cap of $116.88 million, a PE ratio of -0.91 and a beta of 0.66. LENZ Therapeutics has a 1-year low of $3.60 and a 1-year high of $50.40. The stock has a 50-day moving average of $4.97 and a 200-day moving average of $7.06.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.03. LENZ Therapeutics had a negative return on equity of 53.39% and a negative net margin of 586.74%.The business had revenue of $5.49 million for the quarter, compared to analyst estimates of $2.38 million. As a group, equities research analysts forecast that LENZ Therapeutics will post -4.18 earnings per share for the current fiscal year.

About LENZ Therapeutics

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for people with presbyopia, an age-related condition that reduces the eye’s ability to focus on near objects. The company’s lead product is VIZZ (aceclidine hydrochloride ophthalmic solution), a prescription eye drop designed to improve near vision by creating a pinhole effect through pupil modulation while aiming to preserve distance vision.

In July 2025, the U.S. Food and Drug Administration approved VIZZ for the treatment of presbyopia in adults.